Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.21 USD
-0.05 (-1.17%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.20 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VNDA 4.21 -0.05(-1.17%)
Will VNDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for VNDA
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...
Q2 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Projects Cash Holdings of $280M-$320M by End of 2025
Vanda Pharmaceuticals (VNDA) Reports Lower Q2 Revenue than Expected
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year